Filtered By:
Specialty: Drugs & Pharmacology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 688 results found since Jan 2013.
Hemorrhagic risk factors after rt PA thrombolysis in acute cerebral infarction
CONCLUSIONS: The establishment of a prediction model based on the risk factors of HT after rt-PA thrombolysis had a good predictive value in patients with ACI. This model was helpful in guiding clinical judgment and improving the safety of intravenous thrombolysis. Early identification of symptomatic bleeding risk factors provided a reference for clinical treatment and prognostic measures of patients with ACI.PMID:37401290 | DOI:10.26355/eurrev_202306_32791
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: L Liu G-Q Luo Q Liu Z-Y Yang Source Type: research
Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk
Clin Ther. 2023 Jun 26:S0149-2918(23)00192-3. doi: 10.1016/j.clinthera.2023.05.007. Online ahead of print.ABSTRACTPURPOSE: The effectiveness and tolerability of a reduced dose (110 mg) of dabigatran versus the standard dose (150 mg) were evaluated in subgroups of patients with atrial fibrillation (AF) at high bleeding risk.METHODS: Eligible patients were adults with AF and a creatinine clearance rate ≥30 mL/min who were initiated on treatment with dabigatran (index) between 2016 and 2018. High-bleeding-risk subgroups were identified: (1) age ≥80 years; (2) moderate renal impairment (creatinine clearance rate 30-<50 ...
Source: Clinical Therapeutics - June 28, 2023 Category: Drugs & Pharmacology Authors: Jaejin An T Craig Cheetham Tiffany Luong Daniel T Lang Ming-Sum Lee Kristi Reynolds Source Type: research
Predicting treatment effects of a new-to-market drug in clinical practice based on phase III randomized trial results
Clin Pharmacol Ther. 2023 Jun 26. doi: 10.1002/cpt.2983. Online ahead of print.ABSTRACTTrial results may not be generalizable to target populations treated in clinical practice with different distributions of baseline characteristics that modify the treatment effect. We used outcome models developed with trial data to predict treatment effects in Medicare populations. We used data from the Randomized Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY), which investigated the effect of dabigatran vs. warfarin on stroke or systemic embolism (stroke/SE) among patients with atrial fibrillation. We developed outcome m...
Source: Clinical Pharmacology and Therapeutics - June 27, 2023 Category: Drugs & Pharmacology Authors: HoJin Shin Shirley V Wang Dae Hyun Kim Ethan Alt Mufaddal Mahesri Lily G Bessette Sebastian Schneeweiss Mehdi Najafzadeh Source Type: research
Effect of frailty on major bleeding in octogenarian patients undergoing percutaneous coronary intervention
CONCLUSIONS: Frailty is an independent predictor of major bleeding in patients undergoing PCI for acute coronary syndrome. Use of the P2Y12 inhibitor ticagrelor increases the risk of major bleeding in frail patients.PMID:37318490 | DOI:10.26355/eurrev_202306_32633
Source: European Review for Medical and Pharmacological Sciences - June 15, 2023 Category: Drugs & Pharmacology Authors: K Özbek A Balun Source Type: research
